Abcellera

Abcellera company information, Employees & Contact Information

Explore related pages

Related company profiles:

AbCellera is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology.

Company Details

Employees
617
Founded
-
Address
150 W 4th Ave, Vancouver,british Columbia V5y 1g4,canada
Phone
(604) 559-9005
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Vancouver, British Columbia
Looking for a particular Abcellera employee's phone or email?

Abcellera Questions

News

AbCellera's Platforms - AbCellera

AbCellera's Platforms AbCellera

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 - Business Wire

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 Business Wire

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 - Yahoo Finance

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 Yahoo Finance

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 - Investing News Network

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 Investing News Network

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - sharewise.com

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause sharewise.com

ABCL575 - AbCellera

ABCL575 AbCellera

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 - Investing News Network

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 Investing News Network

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - Yahoo Finance

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 Yahoo Finance

AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire

AbCellera to Participate at Upcoming Investor Conferences in September Business Wire

ABCL635 - AbCellera

ABCL635 AbCellera

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Yahoo Finance

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Yahoo Finance

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer - Business Wire

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer Business Wire

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 - Yahoo Finance

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 Yahoo Finance

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 Business Wire

Making medicines together. We collaborate with partners to create differentiated antibody medicines. - AbCellera

Making medicines together. We collaborate with partners to create differentiated antibody medicines. AbCellera

AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Yahoo Finance

AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit Yahoo Finance

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology - Business Wire

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology Business Wire

PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer - AbCellera

PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer AbCellera

AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease - Business Wire

AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease Business Wire

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies - Business Wire

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies Business Wire

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies - Business Wire

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies Business Wire

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines - Business Wire

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines Business Wire

Prelude Therapeutics and AbCellera Enter Partnership to - GlobeNewswire

Prelude Therapeutics and AbCellera Enter Partnership to GlobeNewswire

Rapid response through the entrepreneurial capabilities of academic scientists - Nature

Rapid response through the entrepreneurial capabilities of academic scientists Nature

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19 - PR Newswire

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19 PR Newswire

abcl-ex991_6.htm - SEC.gov

abcl-ex991_6.htm SEC.gov

AbCellera: Burning Cash, Searching For 'Blockbusters' - Seeking Alpha

AbCellera: Burning Cash, Searching For 'Blockbusters' Seeking Alpha

AbCellera Biologics: Still A Concept Stock (NASDAQ:ABCL) - Seeking Alpha

AbCellera Biologics: Still A Concept Stock (NASDAQ:ABCL) Seeking Alpha

AbCellera Stock: A Platform To Pipeline Transition (NASDAQ:ABCL) - Seeking Alpha

AbCellera Stock: A Platform To Pipeline Transition (NASDAQ:ABCL) Seeking Alpha

AbCellera CEO weighs in on AI in antibody drug discovery - drugdiscoverytrends.com

AbCellera CEO weighs in on AI in antibody drug discovery drugdiscoverytrends.com

AbCellera to Present at Upcoming Investor Conferences in November 2024 | User | wapakdailynews.com - FinancialContent

AbCellera to Present at Upcoming Investor Conferences in November 2024 | User | wapakdailynews.com FinancialContent

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023 | User | wapakdailynews.com - FinancialContent

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023 | User | wapakdailynews.com FinancialContent

Down 57%, Is AbCellera Biologics a Buy on the Dip? - The Motley Fool

Down 57%, Is AbCellera Biologics a Buy on the Dip? The Motley Fool

AbCellera Biologics (ABCL) Stock Price, News & Analysis - MarketBeat

AbCellera Biologics (ABCL) Stock Price, News & Analysis MarketBeat

A View from the CT Foxhole: Brad Ringeisen, Executive Director, Innovative Genomics Institute - Combating Terrorism Center at West Point

A View from the CT Foxhole: Brad Ringeisen, Executive Director, Innovative Genomics Institute Combating Terrorism Center at West Point

B.C. strengthens clinical research bringing more jobs, better care to people - BC Gov News

B.C. strengthens clinical research bringing more jobs, better care to people BC Gov News

Abcellera IPO rockets upward with $555.5M in gross proceeds - BioWorld MedTech

Abcellera IPO rockets upward with $555.5M in gross proceeds BioWorld MedTech

Channel Bio opens new state-of-the-art facility in Sydney - BiotechDispatch

Channel Bio opens new state-of-the-art facility in Sydney BiotechDispatch

AbCellera officially closes initial public offering with $555.5 million gross proceeds - BetaKit

AbCellera officially closes initial public offering with $555.5 million gross proceeds BetaKit

Meet Canada’s EY Entrepreneur Of The Year® 2021 national award winners | EY - Canada - EY

Meet Canada’s EY Entrepreneur Of The Year® 2021 national award winners | EY - Canada EY

The Impact of Coronavirus on Sustainability - ArcGIS StoryMaps

The Impact of Coronavirus on Sustainability ArcGIS StoryMaps

adMare Launches Abdera with AbCellera as a Founding Partner - PR Newswire Canada

adMare Launches Abdera with AbCellera as a Founding Partner PR Newswire Canada

Life Sciences 2022 - Business in Vancouver

Life Sciences 2022 Business in Vancouver

Construction underway on final phase of AbCellera headquarters in Vancouver - Daily Hive Vancouver

Construction underway on final phase of AbCellera headquarters in Vancouver Daily Hive Vancouver

AbCellera to build therapeutic antibodies manufacturing facility in False Creek Flats - Daily Hive Vancouver

AbCellera to build therapeutic antibodies manufacturing facility in False Creek Flats Daily Hive Vancouver

Top Abcellera Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant